Chad Robins, Author at TechCrunch

Chad Robins is CEO and co-founder of Adaptive Biotechnologies (Nasdaq: ADPT), a commercial biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since its founding in 2009, Chad has led Adaptive in building a proprietary immune medicine platform that powers life sciences research, clinical diagnostics, and drug discovery businesses. Chad is actively involved in the biotechnology and healthcare policy communities, serving on the board of Life Science Washington and the steering committee of the Coalition for 21st Century Medicine. In addition to serving as Chairman of the Board of Adaptive, he also serves on the boards of AltPep, AdvaMedDx, and HeadLight. Chad graduated with honors from Cornell University and earned an MBA from The Wharton School of the University of Pennsylvania. Prior to Adaptive, Chad held leadership positions in real estate, investment banking, private equity, and medical technology.